FDA Clearance Tracker · P240005
enVista Envy hydrophobic acrylic intraocular lens (IOL), enVista Envy toric hydrophobic acrylic intraocular lens (IOL)
Last checked: Nov 19, 2026Latest source record: Oct 10, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Oct 10, 2024
Approved
Time to decision
216 days
Received Mar 8, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P240005
- Device name
- enVista Envy hydrophobic acrylic intraocular lens (IOL), enVista Envy toric hydrophobic acrylic intraocular lens (IOL)
- Applicant
- Bausch & Lomb, Inc.
- Applicant location
- Rochester, NY
- Received
- Mar 8, 2024
- Decided
- Oct 10, 2024
- Decision
- Approved
- Supplements
- 10 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Lens, multifocal intraocular (MFK)
- Device class
- Class III
- Regulation
- 21 CFR 886.3600
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for the enVista Envy hydrophobic acrylic intraocular lens (IOL) and the enVista Envy toric hydrophobic acrylic IOL. The enVista Envy hydrophobic acrylic IOL (non-preloaded model: EN / preloaded into shuttle model: EPN) is indicated for primary implantation in the capsular bag of the eye in adult patients for the visual correction of aphakia with less than or equal to 1.0 D preoperative corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL. The enVista Envy Toric hydrophobic acrylic IOL (non-preloaded model: ETN / preloaded into shuttle model: ETPN) is indicated for primary implantation in the capsular bag of the eye in adult patients for the visual correction of aphakia and corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MFK. The earliest in FDA's data is P960028, decided Sep 5, 1997.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Bausch & Lomb, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Bausch + Lomb Multifocal for Astigmatism (kalifilcon A) One-Day Soft (hydrophilic) Contact Lens510(k)
K262941 · Decided Oct 16, 2026 · 56 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
K192005 · Decided Oct 4, 2019 · 67 days after receipt
Device type: Folders And Injectors, Intraocular Lens (Iol) (MSS) · Ophthalmology
P910056-S027 · Decided Jun 8, 2018 · 221 days after receipt · Panel Track
Device type: LENS, INTRAOCULAR, TORIC OPTICS (MJP) · Ophthalmology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.